People
With the COVID-19 pandemic closing physicians’ offices and causing patients to think twice about exposing themselves in healthcare settings, Neurocrine is delaying its launch of Ongentysis®.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
The company announced that one of its antibodies, STI-1499, has shown 100% inhibition of SARS-CoV-2 in laboratory tests.
Earlier this week, Sanofi’s chief executive officer Paul Hudson indicated that the U.S. would have first access to its COVID-19 vaccine because of the significant financial support it is receiving from the U.S. government.
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
A gene therapy that eliminates the need for radical cystectomies (complete removal of the bladder) in a particular, aggressive form of bladder cancer is undergoing Priority Review by the U.S. Food and Drug Administration.
Researchers at a New York hospital compared Abbott’s 15-minute Abbott ID NOW test to another COVID-19 diagnostics device and found that the Abbott system missed 48% of positive cases the other device detected.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
Following the announcement that Slaoui was tapped to helm Operation Warp Speed, Jim Greenwood, president and CEO of BIO, hailed that decision.
“VLPs have special immunological properties and are processed differently by the immune system so they have longer duration,” Adam Simpson, CEO of Icosavax, told BioSpace.
PRESS RELEASES